These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 34357961)

  • 61. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
    Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
    J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.
    de Almeida LP; Ross CA; Zala D; Aebischer P; Déglon N
    J Neurosci; 2002 May; 22(9):3473-83. PubMed ID: 11978824
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Excess Rab4 rescues synaptic and behavioral dysfunction caused by defective HTT-Rab4 axonal transport in Huntington's disease.
    White JA; Krzystek TJ; Hoffmar-Glennon H; Thant C; Zimmerman K; Iacobucci G; Vail J; Thurston L; Rahman S; Gunawardena S
    Acta Neuropathol Commun; 2020 Jul; 8(1):97. PubMed ID: 32611447
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Co-occurrence of mixed proteinopathies in late-stage Huntington's disease.
    St-Amour I; Turgeon A; Goupil C; Planel E; Hébert SS
    Acta Neuropathol; 2018 Feb; 135(2):249-265. PubMed ID: 29134321
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A high-throughput screening to identify small molecules that suppress huntingtin promoter activity or activate huntingtin-antisense promoter activity.
    Khaled HG; Feng H; Hu X; Sun X; Zheng W; Li PP; Rudnicki DD; Ye W; Chen YC; Southall N; Marugan J; Ross CA; Ferrer M; Henderson MJ; Margolis RL
    Sci Rep; 2021 Mar; 11(1):6157. PubMed ID: 33731741
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Huntingtin-Lowering Therapies for Huntington Disease: A Review of the Evidence of Potential Benefits and Risks.
    Leavitt BR; Kordasiewicz HB; Schobel SA
    JAMA Neurol; 2020 Jun; 77(6):764-772. PubMed ID: 32202594
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.
    Hu J; Liu J; Corey DR
    Chem Biol; 2010 Nov; 17(11):1183-8. PubMed ID: 21095568
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Parent-of-origin differences of mutant HTT CAG repeat instability in Huntington's disease.
    Aziz NA; van Belzen MJ; Coops ID; Belfroid RD; Roos RA
    Eur J Med Genet; 2011; 54(4):e413-8. PubMed ID: 21540131
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Nuclear retention of full-length HTT RNA is mediated by splicing factors MBNL1 and U2AF65.
    Sun X; Li PP; Zhu S; Cohen R; Marque LO; Ross CA; Pulst SM; Chan HY; Margolis RL; Rudnicki DD
    Sci Rep; 2015 Jul; 5():12521. PubMed ID: 26218986
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Murine Models of Huntington's Disease for Evaluating Therapeutics.
    Kosior N; Leavitt BR
    Methods Mol Biol; 2018; 1780():179-207. PubMed ID: 29856020
    [TBL] [Abstract][Full Text] [Related]  

  • 73. In Vivo Multidimensional Brain Imaging in Huntington's Disease Animal Models.
    Flament J; Hantraye P; Valette J
    Methods Mol Biol; 2018; 1780():285-301. PubMed ID: 29856025
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Juvenile Huntington's Disease Skin Fibroblasts Respond with Elevated Parkin Level and Increased Proteasome Activity as a Potential Mechanism to Counterbalance the Pathological Consequences of Mutant Huntingtin Protein.
    Aladdin A; Király R; Boto P; Regdon Z; Tar K
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31717806
    [TBL] [Abstract][Full Text] [Related]  

  • 75. HD CAGnome: a search tool for huntingtin CAG repeat length-correlated genes.
    Galkina EI; Shin A; Coser KR; Shioda T; Kohane IS; Seong IS; Wheeler VC; Gusella JF; Macdonald ME; Lee JM
    PLoS One; 2014; 9(4):e95556. PubMed ID: 24751919
    [TBL] [Abstract][Full Text] [Related]  

  • 76. N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy.
    Liu X; Wang CE; Hong Y; Zhao T; Wang G; Gaertig MA; Sun M; Li S; Li XJ
    PLoS Genet; 2016 May; 12(5):e1006083. PubMed ID: 27203582
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.
    Suelves N; Kirkham-McCarthy L; Lahue RS; Ginés S
    Sci Rep; 2017 Jul; 7(1):6082. PubMed ID: 28729730
    [TBL] [Abstract][Full Text] [Related]  

  • 78. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking.
    Orr AL; Li S; Wang CE; Li H; Wang J; Rong J; Xu X; Mastroberardino PG; Greenamyre JT; Li XJ
    J Neurosci; 2008 Mar; 28(11):2783-92. PubMed ID: 18337408
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Exploring the role of high-mobility group box 1 (HMGB1) protein in the pathogenesis of Huntington's disease.
    Angelopoulou E; Paudel YN; Piperi C
    J Mol Med (Berl); 2020 Mar; 98(3):325-334. PubMed ID: 32036391
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington's disease.
    Yin X; Manczak M; Reddy PH
    Hum Mol Genet; 2016 May; 25(9):1739-53. PubMed ID: 26908605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.